Comparisons of Post-Load Glucose at Different Time Points for Identifying High Risks of MASLD Progression

Overview

Journal Nutrients

Date 2025 Jan 11

PMID 39796589

Authors

Long Teng

Ling Luo

Yanhong Sun

Wei Wang

Zhi Dong

Xiaopei Cao

Junzhao Ye

Bihui Zhong

Affiliations

Soon will be listed here.

Abstract

: The 1-h post-load plasma glucose was proposed to replace the current OGTT criteria for diagnosing prediabetes/diabetes. However, it remains unclear whether it is superior in identifying progressive metabolic dysfunction-associated steatotic liver disease (MASLD), and thus we aimed to clarify this issue. : Consecutive Asian participants (non-MASLD, = 1049; MASLD, = 1165) were retrospectively enrolled between June 2012 and June 2024. CT was used to quantify liver steatosis, while the serum liver fibrotic marker was used to evaluate liver fibrosis. : Compared with those with normal levels of both 1-h post-glucose (1hPG) and 2-h post-glucose (2hPG), patients with MASLD showed a significant positive association between elevated 1hPG levels and moderate to severe liver steatosis (odds ratio [OR] = 2.19, 95% confidence interval [CI]: 1.13-4.25, = 0.02]. Elevated levels of both 1hPG and 2hPG were associated with an increased risk of liver injury (OR = 2.03, 95% CI: 1.44-2.86, < 0.001). Elevated 2hPG levels with or without elevated 1hPG levels were associated with liver fibrosis (OR = 1.99, 95% CI: 1.15-3.45, < 0.001; OR = 2.72, 95% CI: 1.79-4.11, < 0.001, respectively). Additionally, either 1hPG or 2hPG levels were associated with atherosclerosis, revealing significant dose-dependent associations between glucose status and atherosclerosis risk (OR = 2.77, 95% CI: 1.55-4.96, < 0.001 for elevated 1hPG; OR = 2.98, 95% CI = 1.54-5.78, = 0.001 for elevated 2hPG; OR = 2.41, 95% CI = 1.38-4.21, = 0.001 for elevated levels of both 1hPG and 2hPG). The areas under the ROC for predicting steatosis, liver injury, liver fibrosis, and atherosclerosis were 0.64, 0.58, 0.58, and 0.64 for elevated 1hPG (all < 0.05) and 0.50, 0.60, 0.56, and 0.62 for elevated 2hPG (all < 0.05), respectively. : These findings underscore the necessity for clinicians to acknowledge that the screening and management of MALSD requires the monitoring of 1hPG levels.

References

Younossi Z, Golabi P, Paik J, Henry A, Van Dongen C, Henry L . The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023; 77(4):1335-1347. PMC: 10026948. DOI: 10.1097/HEP.0000000000000004. View

Boyce C, Pickhardt P, Kim D, Taylor A, Winter T, Bruce R . Hepatic steatosis (fatty liver disease) in asymptomatic adults identified by unenhanced low-dose CT. AJR Am J Roentgenol. 2010; 194(3):623-8. DOI: 10.2214/AJR.09.2590. View

Cefalo C, Riccio A, Fiorentino T, Succurro E, Mannino G, Perticone M . Pathophysiological characteristics of subjects with intermediate hyperglycemia and type 2 diabetes identified by 1-hour plasma glucose during an oral glucose tolerance test. Diabetes Res Clin Pract. 2024; 217:111856. DOI: 10.1016/j.diabres.2024.111856. View

Kilinc S, Demirbas T, Atay E, Ceran O, Atay Z . Elevated 1-h post-load plasma glucose levels in normal glucose tolerance children with obesity is associated with early carotid atherosclerosis. Obes Res Clin Pract. 2020; 14(2):136-141. DOI: 10.1016/j.orcp.2020.02.001. View

Bergman M, Manco M, Satman I, Chan J, Schmidt M, Sesti G . International Diabetes Federation Position Statement on the 1-hour post-load plasma glucose for the diagnosis of intermediate hyperglycaemia and type 2 diabetes. Diabetes Res Clin Pract. 2024; 209:111589. DOI: 10.1016/j.diabres.2024.111589. View

Miao L, Targher G, Byrne C, Cao Y, Zheng M . Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab. 2024; 35(8):697-707. DOI: 10.1016/j.tem.2024.02.007. View

Della Pepa G, Lupoli R, Masulli M, Boccia R, De Angelis R, Gianfrancesco S . Blood glucose control and metabolic dysfunction-associated steatotic liver disease in people with type 1 diabetes. J Endocrinol Invest. 2024; 47(9):2371-2378. PMC: 11368973. DOI: 10.1007/s40618-024-02333-2. View

Bae J, Lee D, Suh K, Kim H, Lee K, Lee J . Noninvasive assessment of hepatic steatosis using a pathologic reference standard: comparison of CT, MRI, and US-based techniques. Ultrasonography. 2021; 41(2):344-354. PMC: 8942731. DOI: 10.14366/usg.21150. View

Kaul S . Evidence for the Universal Blood Pressure Goal of <130/80 mm Hg Is Strong: Controversies in Hypertension - Con Side of the Argument. Hypertension. 2020; 76(5):1391-1399. DOI: 10.1161/HYPERTENSIONAHA.120.14648. View

10.

Andreozzi F, Mancuso E, Mazza E, Mannino G, Fiorentino T, Arturi F . One-hour post-load glucose levels are associated with hepatic steatosis assessed by transient elastography. Diabetes Obes Metab. 2023; 26(2):682-689. DOI: 10.1111/dom.15358. View

11.

Ferrannini G, De Bacquer D, Gyberg V, De Backer G, Kotseva K, Mellbin L . Saving time by replacing the standardised two-hour oral glucose tolerance test with a one-hour test: Validation of a new screening algorithm in patients with coronary artery disease from the ESC-EORP EUROASPIRE V registry. Diabetes Res Clin Pract. 2021; 183:109156. DOI: 10.1016/j.diabres.2021.109156. View

12.

Levy J, Matthews D, Hermans M . Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998; 21(12):2191-2. DOI: 10.2337/diacare.21.12.2191. View

13.

Pareek M, Bhatt D, Nielsen M, Jagannathan R, Eriksson K, Nilsson P . Enhanced Predictive Capability of a 1-Hour Oral Glucose Tolerance Test: A Prospective Population-Based Cohort Study. Diabetes Care. 2017; 41(1):171-177. DOI: 10.2337/dc17-1351. View

14.

Starekova J, Hernando D, Pickhardt P, Reeder S . Quantification of Liver Fat Content with CT and MRI: State of the Art. Radiology. 2021; 301(2):250-262. PMC: 8574059. DOI: 10.1148/radiol.2021204288. View

15.

. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024; 81(3):492-542. DOI: 10.1016/j.jhep.2024.04.031. View

16.

Rinella M, Lazarus J, Ratziu V, Francque S, Sanyal A, Kanwal F . A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023; 79(6):1542-1556. DOI: 10.1016/j.jhep.2023.06.003. View

17.

Hutchison A, Tavaglione F, Romeo S, Charlton M . Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance. J Hepatol. 2023; 79(6):1524-1541. DOI: 10.1016/j.jhep.2023.08.030. View

18.

Wang T, Zhao Z, Yu X, Zeng T, Xu M, Xu Y . Age-specific modifiable risk factor profiles for cardiovascular disease and all-cause mortality: a nationwide, population-based, prospective cohort study. Lancet Reg Health West Pac. 2022; 17:100277. PMC: 8720788. DOI: 10.1016/j.lanwpc.2021.100277. View

19.

Colagiuri S . Definition and Classification of Diabetes and Prediabetes and Emerging Data on Phenotypes. Endocrinol Metab Clin North Am. 2021; 50(3):319-336. DOI: 10.1016/j.ecl.2021.06.004. View

20.

Pirmoazen A, Khurana A, El Kaffas A, Kamaya A . Quantitative ultrasound approaches for diagnosis and monitoring hepatic steatosis in nonalcoholic fatty liver disease. Theranostics. 2020; 10(9):4277-4289. PMC: 7086372. DOI: 10.7150/thno.40249. View